血清胆固醇与高级别前列腺癌风险:REDUCE研究结果
该研究对REDUCE试验中4974名未使用他汀类药物的男性进行事后分析,所有男性均接受PSA非依赖、研究规定的2年和4年前列腺穿刺活检。结果显示,高总血清胆固醇与高级别前列腺癌诊断风险增加相关(每10 mg/dL OR 1.05;95% CI 1.00-1.09;p=0.048),高HDL与总体(OR 1.08;95% CI 1.01-1.16;p=0.033)和高级别前列腺癌(OR 1.14;95% CI 1.01-1.28;p=0.034)风险增加相关,而LDL与前列腺癌风险无关。
要点
- 高总胆固醇与高级别前列腺癌风险增加相关(每10 mg/dL OR 1.05;95% CI 1.00-1.09;p=0.048)。
- 高HDL与总体和高级别前列腺癌风险增加相关(总体OR 1.08;高级别OR 1.14)。
- LDL与总体、低级别或高级别前列腺癌风险均无关(p值均>0.137)。
核心结论
- 在REDUCE试验中,高总血清胆固醇和高HDL与高级别前列腺癌风险增加相关,支持胆固醇-前列腺癌关联。
研究设计与样本
- REDUCE随机试验的事后分析,纳入4974名未使用他汀类药物的男性,这些男性PSA升高且基线活检阴性,均接受2年和4年研究规定的前列腺穿刺活检。
主要发现
- 高总血清胆固醇与高级别前列腺癌诊断风险增加相关(每10 mg/dL OR 1.05;95% CI 1.00-1.09;p=0.048),但与总体或低级别前列腺癌风险无关(p值>0.185)。
- 血清LDL与总体、低级别或高级别前列腺癌风险均无关(p值>0.137)。
- 高血清HDL与总体前列腺癌风险增加相关(每10 mg/dL OR 1.08;95% CI 1.01-1.16;p=0.033),也与高级别前列腺癌风险增加相关(每10 mg/dL OR 1.14;95% CI 1.01-1.28;p=0.034)。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Epidemiologic evidence for a serum cholesterol-prostate cancer link is mixed. Prostate-specific antigen (PSA) is positively correlated with cholesterol, potentially increasing PSA-driven biopsy recommendations in men with high cholesterol, though biopsy compliance may be lower in men with comorbid conditions. These potential biases may affect PSA-driven biopsy rates and subsequent prostate cancer detection in men with high serum cholesterol. Our objective was to test the association between serum cholesterol and prostate cancer risk in men receiving PSA independent, study-mandated prostate biopsies. METHODS: We conducted a post hoc analysis of data from 4974 non-statin users in REDUCE, a randomized trial in men with elevated PSA and a negative baseline biopsy. Men underwent 2- and 4-year trial-mandated prostate biopsies. Associations between baseline serum levels of total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL) and prostate cancer risk, overall and by Gleason grade (<7 vs. ≥7), were examined using multivariable logistic regression. RESULTS: High total serum cholesterol was associated with an increased risk of high-grade prostate cancer diagnosis (OR per 10 mg/dL 1.05; 95% CI 1.00-1.09; p = 0.048), but cholesterol was unrelated to either overall or low-grade prostate cancer risk (p-values >0.185). There was no association between serum LDL and overall, low- or high-grade prostate cancer risk (p-values >0.137). In contrast, elevated serum HDL was associated with increased risk of both overall (OR per 10 mg/dL 1.08; 95% CI 1.01-1.16; p = 0.033) and high-grade prostate cancer (OR per 10 mg/dL 1.14; 95% CI 1.01-1.28; p = 0.034). CONCLUSIONS: In REDUCE, where all men received PSA independent, trial-mandated biopsies thus ensuring complete prostate cancer ascertainment, high total serum cholesterol and high HDL were associated with increased risk of high-grade prostate cancer, supporting a cholesterol-prostate cancer link.
引用
- Jamnagerwalla J, Howard LE, Allott EH, et al. Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study. Prostate Cancer Prostatic Dis. 2017. PMID: 29282360. doi:10.1038/s41391-017-0030-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。